Pimavanserin
Back to searchMolecule Structure
Scientific Name
Pimavanserin
Description of the Drug
Pimavanserin is a second generation atypical antipsychotic used for the treatment of hallucinations and delusions caused by Parkinson’s Disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB05316
http://www.drugbank.ca/drugs/DB05316
Brand Name(s)
Not Available
Company Owner(s)
Acadia Pharmaceuticals Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Serotonin 2a (5-HT2a) receptor | SINGLE PROTEIN | INVERSE AGONIST | CHEMBL224 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL675165 | ||
Human Metabolome Database | HMDB0256551 | ||
DrugBank | DB05316 | ||
PubChem: Thomson Pharma | 15056570 | ||
PubChem | 10071196 | ||
LINCS | LSM-45960 | ||
BindingDB | 139370 | ||
DrugCentral | 5142 | ||
ChemicalBook | CB8966229 | ||
Guide to Pharmacology | 8423 | ||
rxnorm | PIMAVANSERIN TARTRATE | PIMAVANSERIN | NUPLAZID |
ChEBI | 133017 | ||
ZINC | ZINC000016159083 |